Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), reports developments in Bio-Native AI, biologics discovery, and AI-driven drug development. Company updates focus on the HYFT® technology stack and the LensAI™ platform, which combine computational analysis with wet-lab validation for epitope mapping, de novo molecular design, in silico vaccine exploration, immunogenicity screening, and population-scale biologics analytics.
Recurring news also covers earnings releases, platform commercialization, partnership and customer activity, and portfolio initiatives such as B Cell Llama™ nanobody discovery and dengue vaccine research. Corporate updates include the transition from the ImmunoPrecise brand to MindWalk, the Nasdaq ticker change to HYFT, and portfolio refinements such as the divestiture of the Netherlands antibody-discovery operations.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will host an earnings conference call on Thursday, December 15, 2022, at 10:30 am Eastern Time to discuss its quarterly results and recent business highlights for Q2 fiscal year 2023. The company plans to release its financial results prior to the call. The management will take questions from participants following the presentation. Interested parties can join the call via provided phone numbers and a live webcast, which will also be available for replay on the company's investor relations page.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced a collaboration with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW), focusing on AI-driven antibody discovery for cancer therapies. BioStrand, a subsidiary of IPA, will utilize its LENSai™ software to create clinical molecules. The partnership includes an upfront payment of US$500,000 for BioStrand, along with additional success-based milestones. This initiative aims to enhance the efficiency of developing targeted treatments, aligning with the long-term vision of advancing precision medicine.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced the voluntary delisting of its common shares from the TSX Venture Exchange (TSXV), effective November 25, 2022. The company cites low trading volume on the TSXV as a reason for this decision, believing that delisting will streamline operations and create a central marketplace on NASDAQ, enhancing long-term liquidity and shareholder value. Shareholders can continue trading IPA shares on NASDAQ, with many Canadian brokers providing access.
ImmunoPrecise Antibodies Ltd. (IPA) announced a strategic collaboration through its subsidiary, Talem Therapeutics, with OmniAb, Inc. This multi-target license agreement aims to develop three immuno-oncology programs targeting cancer markers B7H3, CD38, and TIM3. Talem will utilize its advanced laboratory and in silico technologies, including LENSai™, alongside OmniChicken antibody discovery technology. The partnership outlines shared downstream economics and positions Talem to accelerate the development of potential therapies leveraging AI-driven methodologies.
ImmunoPrecise Antibodies (IPA) has announced that its subsidiary, Talem Therapeutics, has received positive results from a study by the National Institute of Allergy and Infectious Diseases (NIAID). The study reaffirms the effectiveness of PolyTope® TATX-03 in neutralizing various SARS-CoV-2 variants, including new Omicron sublineages. IPA's Chief Scientific Officer highlighted the significance of this validation as they prepare for human clinical trials. This independent validation strengthens IPA's position in the market and showcases the product's potential against emerging COVID-19 variants.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported its financial results for Q1 FY2023, ending July 31, 2022. Total revenue rose 2.2% to $4.7 million, driven by increased protein manufacturing services. However, net loss expanded to $9.4 million from $3.2 million year-over-year, mainly due to higher R&D investments totaling $5.8 million, up from $1.1 million. The company's cash position stood at $19.2 million, enough to sustain operations for at least 12 months. Advances in AI-driven antibody discovery and the successful validation of PolyTope TATX-03 therapy were key highlights.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will hold an earnings conference call on September 14, 2022, at 10:30 am Eastern Time, to discuss its first-quarter fiscal year 2023 results. The financial results will be released prior to the call, and management will answer pre-submitted questions from investors. Participants can join via the provided toll-free and toll dial-in numbers. The call will also be accessible online and available for replay on the company’s investor relations page.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reports successful results for its PolyTope® TATX-03 antibody therapy against COVID-19 variants, including the Omicron BA.5 subvariant. Validated by the Max von Pettenkofer Institute, the therapy showcases effectiveness in neutralizing various strains that challenge other commercial products. As the company approaches clinical trials, its Chief Scientific Officer emphasizes the therapy's potential and the urgency for effective COVID-19 treatments amidst evolving variants.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported record revenues of $19.4 million for the fiscal year ended April 30, 2022, an increase of 8.1% from $17.9 million in 2021. The quarterly revenue rose to $5.2 million, up 7.4% year-over-year. However, the company recorded a net loss of $16.7 million, widening from $7.3 million in the previous year. The increase in research and development expenditures also contributed to this loss. As of April 30, 2022, IPA's cash reserves decreased to $30 million from $41.8 million.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced it will host an earnings conference call on July 29, 2022, at 10:30 AM Eastern Time to discuss financial results and business highlights for Q4 and FY 2022. The call aims to engage investors during a Q&A session, with financial results released beforehand. Interested participants can join via toll-free and toll dial-in numbers, or listen live online. The event will be available for replay on the company's investor relations website.